Stocks
AmpliTech Shifts 2026 Focus as Revenue Guidance Uncertain
AmpliTech Group is prioritizing 2026 strategic goals but has withdrawn its $50 million full-year revenue forecast due to deployment timing changes.
#stocks 144 articles
Stocks
Spero Secures Cash Runway to H2 2029 with $105M Financing
Spero Therapeutics has extended its cash runway into the second half of 2029 following a $105 million nondilutive royalty financing. This move,...
Stocks
SES AI Reaffirms 2026 Revenue Target, Eyes 1M Cells Annually
SES AI reaffirms its 2026 revenue guidance of $30M-$35M and aims to produce 1 million NDAA-compliant cells per year starting Q4.
Stocks
Tactile Medical Eyes $360M-$366M 2026 Revenue Target
Tactile Systems Technology (TCMD) projects 2026 revenue between $360 million and $366 million, contingent on normalized airway clearance ordering in Q4. The...
Stocks
Webtoon Forecasts $358M-$368M Q3 Revenue, Targets Double-Digit Q4 Growth
WEBTOON Entertainment Inc. projects Q3 revenue of $358M-$368M, aiming for double-digit growth by Q4's end. This follows a Q2 2026 revenue of...
Stocks
ArcelorMittal Ranks #4 Among Metals Channel Global Mining Titans
ArcelorMittal SA (MT) has been named the #4 broker analyst pick, on average, within the Metals Channel Global Mining Titans Index, according...
Stocks
Upwork Q2: AI Automates Low-End Jobs, Boosts High-Value Contracts
Upwork's Q2 results reveal AI is rapidly automating low-complexity freelance tasks, but simultaneously driving demand for high-value AI consulting and enterprise engagements.
Stocks
Definitive Healthcare Targets $220M-$222M 2026 Revenue, Turbo GA Nears
Definitive Healthcare projects $220M-$222M revenue by 2026, coinciding with the planned general availability of its Turbo product before year-end. This follows a...
Stocks
BMY-AZN Merger Denial Puts Pharma M&A Outlook in Focus
A Financial Times report of BMY-AZN merger talks was swiftly denied by Reuters sources, reigniting debate on Big Pharma M&A prospects. Seeking...